A Brain Capital Grand Strategy: toward economic reimagination

Erin Smith; Diab Ali; Bill Wilkerson; Walter D. Dawson; Kunmi Sobowale; Charles Reynolds; Michael Berk; Helen Lavretsky; Dilip Jeste; Chee H. Ng; Jair C. Soares; Gowri Aragam; Zoe Wainer; Husseini K. Manji; Julio Licinio; Andrew W. Lo; Eric Storch; Ernestine Fu; Marion Leboyer; Ioannis Tarnanas; Agustin Ibanez; Facundo Manes; Sarah Caddick; Howard Fillit; Ryan Abbott; Ian H. Robertson; Sandra B. Chapman; Rhoda Au; Cara M. Altimus; William Hynes; Patrick Brannelly; Jeffrey Cummings; Harris A. Eyre

doi:10.1038/s41380-020-00918-w

A Brain Capital Grand Strategy: toward economic reimagination

Erin Smith, Diab Ali, Bill Wilkerson, Walter D. Dawson, Kunmi Sobowale, Charles Reynolds, Michael Berk, Helen Lavretsky, Dilip Jeste, Chee H. Ng, Jair C. Soares, Gowri Aragam, Zoe Wainer, Husseini K. Manji, Julio Licinio, Andrew W. Lo, Eric Storch, Ernestine Fu, Marion Leboyer, Ioannis TarnanasAgustin Ibanez, Facundo Manes, Sarah Caddick, Howard Fillit, Ryan Abbott, Ian H. Robertson, Sandra B. Chapman, Rhoda Au, Cara M. Altimus, William Hynes, Patrick Brannelly, Jeffrey Cummings, Harris A. Eyre

Neurology

Research output: Contribution to journal › Editorial › peer-review

43 Scopus citations

Original language	English (US)
Pages (from-to)	3-22
Number of pages	20
Journal	Molecular Psychiatry
Volume	26
Issue number	1
DOIs	https://doi.org/10.1038/s41380-020-00918-w
State	Published - Jan 2021

ASJC Scopus subject areas

Psychiatry and Mental health
Cellular and Molecular Neuroscience
Molecular Biology

Access to Document

10.1038/s41380-020-00918-w

Cite this

Smith, E., Ali, D., Wilkerson, B., Dawson, W. D., Sobowale, K., Reynolds, C., Berk, M., Lavretsky, H., Jeste, D., Ng, C. H., Soares, J. C., Aragam, G., Wainer, Z., Manji, H. K., Licinio, J., Lo, A. W., Storch, E., Fu, E., Leboyer, M., ... Eyre, H. A. (2021). A Brain Capital Grand Strategy: toward economic reimagination. Molecular Psychiatry, 26(1), 3-22. https://doi.org/10.1038/s41380-020-00918-w

Smith, E, Ali, D, Wilkerson, B, Dawson, WD, Sobowale, K, Reynolds, C, Berk, M, Lavretsky, H, Jeste, D, Ng, CH, Soares, JC, Aragam, G, Wainer, Z, Manji, HK, Licinio, J, Lo, AW, Storch, E, Fu, E, Leboyer, M, Tarnanas, I, Ibanez, A, Manes, F, Caddick, S, Fillit, H, Abbott, R, Robertson, IH, Chapman, SB, Au, R, Altimus, CM, Hynes, W, Brannelly, P, Cummings, J & Eyre, HA 2021, 'A Brain Capital Grand Strategy: toward economic reimagination', Molecular Psychiatry, vol. 26, no. 1, pp. 3-22. https://doi.org/10.1038/s41380-020-00918-w

@article{1670b5de3073400fbfb95d11d6ebb6d6,

title = "A Brain Capital Grand Strategy: toward economic reimagination",

author = "Erin Smith and Diab Ali and Bill Wilkerson and Dawson, {Walter D.} and Kunmi Sobowale and Charles Reynolds and Michael Berk and Helen Lavretsky and Dilip Jeste and Ng, {Chee H.} and Soares, {Jair C.} and Gowri Aragam and Zoe Wainer and Manji, {Husseini K.} and Julio Licinio and Lo, {Andrew W.} and Eric Storch and Ernestine Fu and Marion Leboyer and Ioannis Tarnanas and Agustin Ibanez and Facundo Manes and Sarah Caddick and Howard Fillit and Ryan Abbott and Robertson, {Ian H.} and Chapman, {Sandra B.} and Rhoda Au and Altimus, {Cara M.} and William Hynes and Patrick Brannelly and Jeffrey Cummings and Eyre, {Harris A.}",

note = "Funding Information: Conflict of interest JC has provided consultation to Acadia, Actino-gen, Alkahest, Alzheon, AnnovisBio, Avanir, Axsome, BiOasis, Biogen, Cassava, Cerecin, Cortexyme, Cytox, Diadem, EIP Pharma, Eisai, Foresight, GemVax, Genentech, Green Valley, Grifols, Map-light, Merck, Otsuka, Resverlogix, Roche, Samumed, Samus, Signant, Third Rock, and United Neuroscience pharmaceutical and assessment companies. JC has stock options in ADAMAS, MedAvante, QR pharma/AnnovisBio, BiOasis. Ryan Abbott works as an attorney and consult to a variety of commercial enterprises in the life science and information technology fields. AWL reports personal investments in public and private biotech companies, biotech venture capital funds, and biotech mutual funds. He is a director of BridgeBio Pharma and Roivant Sciences, and a member of the Board of Overseers at Beth Israel Deaconess Medical Center and the NIH{\textquoteright}s National Center for Advancing Translational Sciences Advisory Council and Cures Acceleration Network Review Board. He is a co-founder and partner of QLS Advisors, a health care analytics company; an advisor to BrightEdge Ventures, the impact fund of the American Cancer Society; and chairman emeritus and senior advisor to AlphaSimplex Group, an asset management company he founded in 1999. CR receives a stipend from the American Association for Geriatric Psychiatry for editing the American Journal of Geriatric Psychiatry; royalty income from the University of Pittsburgh as co-inventor of the Pittsburgh Sleep Quality Inventory. IT reports income and stock in ALTOIDA LLC and has a patent “Apparatus, method and program for determining a cognitive state of a user of a mobile device” pending. HAE receives fees from PRODEO LLC, PreActive Technologies INC and ALTOIDA LLC. CHN had served as a consultant for Lundbeck, Grunbiotics, Servier, Janssen-Cilag, and Eli Lilly, received research grant support from Lundbeck, and speaker honoraria from Servier, Lundbeck, Bristol-Myers Squibb, Organon, Eli Lilly, GlaxoSmithK-line, Janssen-Cilag, Astra-Zenaca, Wyeth, and Pfizer. WDD reports personal fees from Commonwealth Fund, personal fees from AARP, personal fees from Insights to Illuminate, LLC, personal fees from Cognitive Solutions, LLC, personal fees from Oregon Health Care Association, personal fees from Mather LifeWays, personal fees from Splaine Consulting, outside the submitted work. E. Storch reports consulting fees from Levo Therapeutics; Honoraria from International OCD Foundation; and book royalties from Wiley, Elsevier, Springer, American Psychological Association, Oxford, Jessica Kingsley, Funding Information: Funding KS is supported by NIMH, Training the Science of Child Mental Health Treatment, 5T32MH073517-14. MB is supported by a NHMRC Senior Principal Research Fellowship (1059660 and 1156072). JC is supported by KMA; NIGMS grant P20GM109025; NINDS grant U01NS093334; and NIA grant R01AG053798. No other co-authors have funding support to note. AWL gratefully acknowledges funding support from Jean-Jacques DeGroof and other sponsors of the MIT Laboratory for Financial Engineering (https://lfe. mit.edu/about/sponsors/). No funding bodies of AWL had any role in study design, data collection and analysis, decision to publish, or preparation of this paper. No direct funding was received for this study by AWL, who was personally salaried by his institution during the period of writing (though no specific salary was set aside for or given to AWL for the writing of this paper). DJ{\textquoteright}s work was supported, in part, by the National Institute of Mental Health R01 grant (R01MH094151-01 to DJ [PI]), and the Sam and Rose Stein Institute for Research on Aging at the University of California San Diego. WDD reports funding from GBHI ALZ UK-20-640170 and from Oregon Health Authority. HL receives grant funding from NIMH, NIA, NCCIH, NIAMS, PCORI, Alzheimer{\textquoteright}s Research and Prevention Foundation. E. Storch reports research support from NIH, Texas Higher Education Coordinating Board, Red Cross, Greater Houston Community Foundation, ReBuild Texas. AI is partially supported by grants from CONICET, ANID/FONDAP/15150012, the Interamerican Development Bank (IDB), GBHI ALZ UK-20-639295, and the Multi-partner Consortium to Expand Dementia Research in Latin America (ReDLat; NIH NIA R01 AG057234, Alzheimer{\textquoteright}s Association SG-20-725707, Tau Consortium, and Global Brain Health Institute).",

year = "2021",

month = jan,

doi = "10.1038/s41380-020-00918-w",

language = "English (US)",

volume = "26",

pages = "3--22",

journal = "Molecular Psychiatry",

issn = "1359-4184",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - A Brain Capital Grand Strategy

T2 - toward economic reimagination

AU - Smith, Erin

AU - Ali, Diab

AU - Wilkerson, Bill

AU - Dawson, Walter D.

AU - Sobowale, Kunmi

AU - Reynolds, Charles

AU - Berk, Michael

AU - Lavretsky, Helen

AU - Jeste, Dilip

AU - Ng, Chee H.

AU - Soares, Jair C.

AU - Aragam, Gowri

AU - Wainer, Zoe

AU - Manji, Husseini K.

AU - Licinio, Julio

AU - Lo, Andrew W.

AU - Storch, Eric

AU - Fu, Ernestine

AU - Leboyer, Marion

AU - Tarnanas, Ioannis

AU - Ibanez, Agustin

AU - Manes, Facundo

AU - Caddick, Sarah

AU - Fillit, Howard

AU - Abbott, Ryan

AU - Robertson, Ian H.

AU - Chapman, Sandra B.

AU - Au, Rhoda

AU - Altimus, Cara M.

AU - Hynes, William

AU - Brannelly, Patrick

AU - Cummings, Jeffrey

AU - Eyre, Harris A.

N1 - Funding Information: Conflict of interest JC has provided consultation to Acadia, Actino-gen, Alkahest, Alzheon, AnnovisBio, Avanir, Axsome, BiOasis, Biogen, Cassava, Cerecin, Cortexyme, Cytox, Diadem, EIP Pharma, Eisai, Foresight, GemVax, Genentech, Green Valley, Grifols, Map-light, Merck, Otsuka, Resverlogix, Roche, Samumed, Samus, Signant, Third Rock, and United Neuroscience pharmaceutical and assessment companies. JC has stock options in ADAMAS, MedAvante, QR pharma/AnnovisBio, BiOasis. Ryan Abbott works as an attorney and consult to a variety of commercial enterprises in the life science and information technology fields. AWL reports personal investments in public and private biotech companies, biotech venture capital funds, and biotech mutual funds. He is a director of BridgeBio Pharma and Roivant Sciences, and a member of the Board of Overseers at Beth Israel Deaconess Medical Center and the NIH’s National Center for Advancing Translational Sciences Advisory Council and Cures Acceleration Network Review Board. He is a co-founder and partner of QLS Advisors, a health care analytics company; an advisor to BrightEdge Ventures, the impact fund of the American Cancer Society; and chairman emeritus and senior advisor to AlphaSimplex Group, an asset management company he founded in 1999. CR receives a stipend from the American Association for Geriatric Psychiatry for editing the American Journal of Geriatric Psychiatry; royalty income from the University of Pittsburgh as co-inventor of the Pittsburgh Sleep Quality Inventory. IT reports income and stock in ALTOIDA LLC and has a patent “Apparatus, method and program for determining a cognitive state of a user of a mobile device” pending. HAE receives fees from PRODEO LLC, PreActive Technologies INC and ALTOIDA LLC. CHN had served as a consultant for Lundbeck, Grunbiotics, Servier, Janssen-Cilag, and Eli Lilly, received research grant support from Lundbeck, and speaker honoraria from Servier, Lundbeck, Bristol-Myers Squibb, Organon, Eli Lilly, GlaxoSmithK-line, Janssen-Cilag, Astra-Zenaca, Wyeth, and Pfizer. WDD reports personal fees from Commonwealth Fund, personal fees from AARP, personal fees from Insights to Illuminate, LLC, personal fees from Cognitive Solutions, LLC, personal fees from Oregon Health Care Association, personal fees from Mather LifeWays, personal fees from Splaine Consulting, outside the submitted work. E. Storch reports consulting fees from Levo Therapeutics; Honoraria from International OCD Foundation; and book royalties from Wiley, Elsevier, Springer, American Psychological Association, Oxford, Jessica Kingsley, Funding Information: Funding KS is supported by NIMH, Training the Science of Child Mental Health Treatment, 5T32MH073517-14. MB is supported by a NHMRC Senior Principal Research Fellowship (1059660 and 1156072). JC is supported by KMA; NIGMS grant P20GM109025; NINDS grant U01NS093334; and NIA grant R01AG053798. No other co-authors have funding support to note. AWL gratefully acknowledges funding support from Jean-Jacques DeGroof and other sponsors of the MIT Laboratory for Financial Engineering (https://lfe. mit.edu/about/sponsors/). No funding bodies of AWL had any role in study design, data collection and analysis, decision to publish, or preparation of this paper. No direct funding was received for this study by AWL, who was personally salaried by his institution during the period of writing (though no specific salary was set aside for or given to AWL for the writing of this paper). DJ’s work was supported, in part, by the National Institute of Mental Health R01 grant (R01MH094151-01 to DJ [PI]), and the Sam and Rose Stein Institute for Research on Aging at the University of California San Diego. WDD reports funding from GBHI ALZ UK-20-640170 and from Oregon Health Authority. HL receives grant funding from NIMH, NIA, NCCIH, NIAMS, PCORI, Alzheimer’s Research and Prevention Foundation. E. Storch reports research support from NIH, Texas Higher Education Coordinating Board, Red Cross, Greater Houston Community Foundation, ReBuild Texas. AI is partially supported by grants from CONICET, ANID/FONDAP/15150012, the Interamerican Development Bank (IDB), GBHI ALZ UK-20-639295, and the Multi-partner Consortium to Expand Dementia Research in Latin America (ReDLat; NIH NIA R01 AG057234, Alzheimer’s Association SG-20-725707, Tau Consortium, and Global Brain Health Institute).

PY - 2021/1

Y1 - 2021/1

UR - http://www.scopus.com/inward/record.url?scp=85093931550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85093931550&partnerID=8YFLogxK

U2 - 10.1038/s41380-020-00918-w

DO - 10.1038/s41380-020-00918-w

M3 - Editorial

C2 - 33100330

AN - SCOPUS:85093931550

SN - 1359-4184

VL - 26

SP - 3

EP - 22

JO - Molecular Psychiatry

JF - Molecular Psychiatry

IS - 1

ER -

A Brain Capital Grand Strategy: toward economic reimagination

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this